39 results about "Fluticasone" patented technology

The invention discloses fluticasone propionate emulsifiable paste and a preparation method thereof. The preparation method of the fluticasone propionate emulsifiable paste comprises the following steps: S1, mixing liquid paraffin, isopropyl myristate and other auxiliaries, and heating to obtain an oil phase; s2, purified water, propylene glycol, disodium hydrogen phosphate dodecahydrate and other auxiliaries are mixed to obtain a water phase; and S3, adding the oil phase into the water phase, adding fluticasone propionate and the like after complete emulsification, uniformly stirring, and standing to obtain the cream. Compared with the prior art, the fluticasone propionate emulsifiable paste prepared by the invention is not easy to layer at high and low temperatures, and the obtained emulsifiable paste has better stability and is very beneficial to transportation, storage and the like of the product.

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

The invention relates to the technical field of external medicine, and discloses a stable external medicine composition containing fluticasone propionate, which comprises the following components: 0.05% of fluticasone propionate; 10.00% of propylene glycol; 0.05% of triethanolamine; 0.20% of imidazolidinyl urea; 0.8% to 1.2% of carbomer; 5%-20% of paraffin; 0.75% of poly (simtrol); 5.00% of isopropyl myristate; and the balance of purified water. Carbomer is added into the stable external pharmaceutical composition containing fluticasone propionate to replace octadecanol in an original formula, so that the high-temperature stability of fluticasone propionate cream is improved in the preparation and optimization process of the fluticasone propionate cream, and the molecular structure of the Carbomer can be matched with other components in the cream, so that the stability of the fluticasone propionate cream is improved. For example, grease phase molecules and water phase molecules form more stable interaction, at high temperature, grease molecules can be effectively prevented from being excessively gathered due to thermal motion, meanwhile, the stability of the water phase can be enhanced, and water is prevented from being separated out of a cream system.

The invention discloses a method for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, which comprises the following steps: heating the suspension for fluticasone propionate aerosol inhalation to be detected, and dissolving auxiliary materials to obtain a solution only containing the raw materials; adding the obtained solution into a heat-insulating dispersing agent, and dispersing again to prepare a sample suspension; and detecting the granularity of the fluticasone propionate in the obtained sample suspension by adopting a laser diffraction method. The invention provides a method suitable for detecting the granularity of raw materials in a suspension for fluticasone propionate aerosol inhalation, the suspension for fluticasone propionate aerosol inhalation is subjected to water bath heating, so that auxiliary materials are dissolved, it is guaranteed that only the fluticasone propionate raw material exists in a sample, the problem of interference of the auxiliary materials in detection of the granularity of the raw materials is avoided, and the detection accuracy of the granularity of the raw materials is improved. The accurate detection of the particle size distribution of the fluticasone propionate raw material in the suspension is realized.

The invention provides a continuous micro-fluidization crystallizer and a preparation method of fluticasone propionate micro-nano particles, and the preparation method comprises the following steps: (1) providing acetone, adding fluticasone propionate into acetone, and preparing an acetone solution of fluticasone propionate; (2) providing water; (3) simultaneously inputting the acetone solution of the fluticasone propionate and water into a continuous micro-fluidization crystallizer according to a ratio, separating out crystals of the fluticasone propionate in the process of mixing the acetone solution of the fluticasone propionate and the water in the continuous micro-fluidization crystallizer, and suspending the formed micro-nano particles in crystal mush; and (4) collecting crystal mush, separating and drying to obtain the fluticasone propionate micro-nano particles, wherein the particle size D90 of the fluticasone propionate micro-nano particles is 1-20 [mu] m. The preparation method of the fluticasone propionate micro-nano particles is suitable for industrial large-scale production, the product quality is stable, the operation is simple, and the requirement on equipment is low.

Disclosed herein are methods of treating or preventing inflammatory diseases of the gastrointestinal (GI) tract by topical administration of a pharmaceutical composition containing a delayed release composition formulated for extended release of corticosteroids into GI tissue.

The present application provides a novel combination preparation for use in the treatment of acute, chronic and allergic rhinosinusitis and / or allergic rhinitis which does not cause dry nasal mucosa and is very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient in the form of a nasal spray.

The invention relates to biodegradable intranasal system for the sustained-release of fluticasone propionate in the intranasal cavity, said system comprising a biodegradable polyester matrix that comprises the fluticasone propionate as the active ingredient to be released in the intranasal cavity, wherein the polyester is selected from the list of poly(L,D-lactic acid) (PLA), poly(caprolactone) (PCL), their copolymers such as PLA-PCL, and mixtures thereof; and a method for preparing said system. The invention also relates to a kit comprising the system of the invention and the means of insertion of the system into the nasal cavity. The invention further relates to fluticasone propionate for use for treating chronic rhinitis or chronic sinusitis, wherein the fluticasone propionate is in a form suitable for administration in the nasal cavity by means of the biodegradable intranasal system of the invention.

The invention relates to the related technical field of measurement of the content of fluticasone propionate emulsifiable paste, in particular to a method for detecting the content of paste by adopting a high performance liquid chromatography, and particularly relates to a method for measuring the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography, in particular to a method for detecting the content of fluticasone propionate emulsifiable paste by adopting the high performance liquid chromatography. Comprising the following steps: preparing a mobile phase from a diammonium hydrogen phosphate buffer solution (the pH value is 2.0-5.0), methanol and acetonitrile by adopting an octadecyl silane bonded silica gel column; and carrying out isocratic elution. According to the method disclosed by the invention, the diammonium hydrogen phosphate buffer solution-methanol-acetonitrile with a specific ratio is adopted as a mobile phase, and a chromatographic system in which an octadecyl silane bonded silica gel column and a guard column are connected in series is combined, so that the interference of oily auxiliary materials in a cream matrix is effectively eliminated, and the detection specificity and the separation effect are remarkably improved; besides, key chromatographic parameters such as column temperature, flow velocity and detection wavelength are optimized, and a scientific test sample pretreatment process is matched, so that the accuracy and reliability of a content measurement result are guaranteed.

The invention provides a method for detecting the content of fluticasone propionate cream. The method comprises the following steps: preparing an internal standard substance solution, preparing a test solution, preparing a reference substance solution, detecting and analyzing. According to the method, the cream is dispersed by heating in a water bath, the problem of uneven dissolution of the cream is solved, and the solution is centrifuged and filtered in a low-temperature environment of 6-10 DEG C to remove matrix impurities, so that the treatment efficiency of a cream sample can be improved, and the influence of personnel operation on a detection result can be effectively reduced; the accuracy of a detection result is improved. Besides, heptyl 4-hydroxybenzoate is selected as an internal standard substance, the retention behavior of heptyl 4-hydroxybenzoate is matched with that of fluticasone propionate, the solubility of heptyl 4-hydroxybenzoate in 65% ethanol is consistent, matrix adsorption and extraction errors can be effectively corrected, and the accuracy and reproducibility are remarkably superior to those of an existing method.

A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone, fluocinonide, or clobetasol. The antifungal and steroid may be within a cream. In one example, a commercially available econazole nitrate cream may be used in conjunction with a commercially available fluocinonide cream or commercially available clobetasol cream to treat the affected skin area.

The invention belongs to the technical field of drug detection, and relates to a UPLC analysis method for the content of a suspension for fluticasone propionate inhalation. In the UPLC detection, isocratic elution is carried out in a chromatographic column by adopting a mobile phase; the volume ratio of the mobile phase A to the mobile phase B is 35: 65-45: 55, the mobile phase B is acetonitrile, the mobile phase A is an aqueous solution of methanol, and the mobile phase A contains 0.045-0.055% by mass of phosphoric acid; octadecylsilane chemically bonded silica is used as a filling agent of the chromatographic column. Through the method, the content of the suspension for inhalation of fluticasone propionate can be rapidly and accurately detected. The method disclosed by the invention is simple to operate, good in specificity, short in detection time and high in accuracy, avoids interference of auxiliary materials in the suspension for inhalation on main components, increases the solubility of the main components, shortens the analysis time, reduces the solvent dosage and reduces the analysis cost.

A composition of fluticasone / linezolid-loaded nanodiamond / polyacrylonitrile nanofibers, consisting of: • Fluticasone propionate in a quantity of 25 mg to 100 mg; • Linezolid in a quantity of 25 mg to 100 mg; • Nanodiamonds dispersed in a concentration of approximately 1 mg / ml dimethylformamide (DMF); and • a polyacrylonitrile (PAN) polymer matrix prepared as a 10% w / v solution in DMF, wherein the drugs, nanodiamonds and PAN are uniformly combined to form an electrospinnable nanocomposite solution, and electrospinning is carried out under conditions suitable for producing nanofibers with controlled drug release, porosity and structural integrity for wound healing applications.

The invention discloses a photothermal stable fluticasone propionate emulsifiable paste preparation and a preparation process thereof, and relates to the technical field of external emulsifiable paste. Comprising the following steps: step 1, (1) adding isopropyl myristate and cetostearyl alcohol into liquid paraffin, mixing, heating and stirring to obtain an oil phase; (2) adding citric acid, sodium citrate, imidazolidinyl urea, a photo-thermal stabilizer and polyethylene glycol hexadecyl-octadecyl ether into deionized water, mixing, heating and stirring to obtain a water phase; (3) adding fluticasone propionate and propylene glycol into deionized water, heating and stirring to obtain a fluticasone propionate solution; and 2, adding the water phase into the oil phase, stirring, adding a fluticasone propionate solution, uniformly mixing, adding propyl hydroxybenzoate and methyl hydroxybenzoate, and standing at room temperature to obtain the fluticasone propionate emulsifiable paste preparation. The fluticasone propionate emulsifiable paste preparation prepared by the invention has good photo-thermal stability and meets the requirements of external emulsifiable paste.

The present application provides a kind of detection method of fluticasone propionate bulk drug particle size, the method is first used to high-power ultrasonic dispersion medium break dispersion medium molecule aggregation, then lower power ultrasonic dispersion system is stabilized, avoid dispersing agent itself aggregation to bulk drug particle is wrapped, form measurement error.In addition, by intermittent electric field, so that particle produces relative displacement or oscillation, while applying ultrasonic dissociation agglomerate, realize the complete wetting of bulk drug particle, stable dispersion and accurate detection, the method is lower to instrument requirement, can realize the accurate detection of strong hydrophobicity bulk drug particle size in the case where not increasing detection cost and detection time.

Disclosed herein is a dosage form of fluticasone propionate for intra-articular administration to a patient with osteoarthritis in a joint.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

The invention relates to a fluticasone pharmaceutical composition and a pharmaceutical preparation thereof. The pharmaceutical composition comprises fluticasone and pharmaceutically acceptable salts thereof, a surfactant, a cosolvent and a thickening agent. In another aspect, the invention provides a pharmaceutical formulation comprising a pharmaceutical composition of the invention. On the other hand, the invention further provides application of the pharmaceutical composition or the pharmaceutical preparation in preparation of drugs for preventing or treating asthma, allergic rhinitis, chronic infarction pneumonia or atopic dermatitis.

This invention provides ACE2 expression inhibitors and their application in ACE2-mediated diseases. It uses human RXRα as a target protein for virtual drug screening and employs computer molecular docking technology to screen compounds with high affinity for the human RXRα receptor. Combined with cell experiments, it screens compounds that inhibit ACE2. The ACE2 expression inhibitors are at least one of ten drugs selected from ursolic acid, phlorizin, resveratrol, triamcinolone, budesonide, fluticasone propionate, vitamin D2, vitamin D3, calcitriol, and alfacalcidol. The ACE2 inhibitors screened by this invention can serve as targeted drugs for ACE2-mediated diseases, providing more drug options for the prevention or treatment of these diseases.

To provide a method for treating a disease.SOLUTION: Provided are potent soft corticosteroids, a pharmaceutical composition comprising the same, and a method for using the same as an anti-inflammatory agent. Also provided is a method for softening fluticasone propionate and similar corticosteroid and attaining a potent but safer alternative. Compounds which are equally as potent as fluticasone but safer than fluticasone, in particular S-fluoromethyl 17α-dichloroacetoxy-6α, 9α-difluoro-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-dien-17β-carbothioate is provided. Another compound of particular interest is 2-hydroxyethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16β-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate.SELECTED DRAWING: None

The application belongs to the technical field of mother liquor recycling, and particularly relates to a treatment method of fluticasone propionate mother liquor. The treatment method of fluticasone propionate mother liquor provided by the application first mixes the fluticasone propionate mother liquor and amine compounds to perform a Hofmann alkylation reaction, quenches fluorohalomethane under mild conditions by using the Hofmann alkylation reaction of the amine compounds, reduces the impurity of fluticasone propionate, and recovers fluticasone propionate with high purity and high recovery rate, so that the material is fully utilized, and the pollution of fluorohalomethane and steroid compounds (fluticasone propionate) to the environment is reduced.

Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E) and ethanol.

A bioactive nanofiber composition for combating biofilm-associated wound infections, comprising: Nanofibers formed from a polymer matrix comprising polyacrylonitrile (PAN) and polyvinyl alcohol (PVA); one or more therapeutic agents selected from fluticasone, mupirocin, ciprofloxacin and silver sulfadiazine; optionally in combination with at least one bioamplifier selected from nanodiamond, graphene oxide and rhamnose; the nanofiber matrix is ​​manufactured in such a way that it achieves the following: a uniform fiber diameter in the range of 100 to 500 nanometers, thereby improving the efficiency of drug encapsulation and release kinetics; a porosity between 70% and 90% to facilitate oxygen exchange and exudate absorption at the wound site; a mechanical tensile strength sufficient to ensure integrity during application and dressing changes; and the composition, through the synergistic combination of ciprofloxacin, mupirocin and silver sulfadiazine, exhibits a broad-spectrum antimicrobial effect against gram-positive and gram-negative biofilm-forming pathogens, thereby promoting sustained drug release and improved wound healing.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a suspension for fluticasone propionate aerosol inhalation and a preparation method thereof. The suspension for fluticasone propionate aerosol inhalation provided by the invention is prepared from fluticasone propionate, isooctanol phosphate, a stabilizer, sodium dihydrogen phosphate, disodium hydrogen phosphate and an osmotic pressure regulator. According to the suspension for the fluticasone propionate aerosol inhalation provided by the invention, the foaming amount of the suspension is obviously reduced and the content uniformity of the suspension is improved by replacing the surfactant with the isooctanol phosphate, so that the product quality of the suspension for the fluticasone propionate aerosol inhalation is ensured.

The invention provides a fluticasone furoate micellar solution. The fluticasone furoate micellar solution comprises fluticasone furoate, a lipophilic component and a nonionic surfactant. According to the fluticasone furoate pharmaceutical composition, the dissolution rate and the absorption rate of fluticasone furoate on nasal mucosa and alveolar mucosa can be remarkably improved, and the administration dosage can be further reduced while the same curative effect is obtained, so that the toxic and side effects are reduced. The aerosol inhalation powder is especially suitable for aerosol inhalation, can provide better pulmonary deposition, and is especially suitable for nasal administration to reduce the administration dosage and improve the bioavailability.

The present application provides a novel combination preparation for us in the treatment of acute, chronic and allergic rhinosinusitis which does not cause dry nasal mucosa and is nevertheless very effective in the treatment of the above diseases. The combination preparation comprises an active ingredient selected from mometasone and / or fluticasone or a pharmaceutically acceptable salt or solvate of any one of the foregoing, in combination with dexpanthenol or a pharmaceutically acceptable salt or solvate thereof, as well as a pharmaceutically acceptable excipient

This invention relates to a method of treatment of asthma comprising a pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation, and wherein the treatment provides an improved baseline-adjusted postdose forced expiratory volume in one second (FEV1) area under the effect curve from time zero to 6 hours (AUEC0-6h) when compared to fluticasone propionate treatment and an improved baseline-adjusted trough FEV1 when compared to albuterol sulfate treatment.

This invention relates to the field of antiviral drug technology, disclosing fluticasone propionate and its application in the preparation of drugs against CHIKV and EEEV. Fluticasone propionate acts on the later stages of the CHIKV and EEEV life cycle. This invention is the first to demonstrate that fluticasone propionate has significant antiviral activity against CHIKV and EEEV, filling the gap in the lack of specific treatments for these two viruses. Furthermore, the fluticasone propionate of this invention is an already marketed drug; repurposing this existing drug can significantly shorten the research and development cycle and is expected to enable rapid clinical application.

Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E) and ethanol.